Abstract | PURPOSE: PATIENTS AND METHODS: Fifty-three patients were enrolled in this trial during the period from May 1998 to October 2000 and received five cycles weekly of Taxol (40 mg/m2) and carboplatin (AUC 1.5) with conventional radiotherapy (40 Gy). Within 3-4 weeks after chemoradiotherapy resection of the primary tumor and the regional neck nodes was performed. RESULTS: Fifty-two patients were evaluable for toxicity and response. Complete response was observed in 31 of 52 patients (CR 60%), and partial remission was seen in 21 of 52 patients (PR 40%). In 30 of 52 patients complete pathologic response (pCR 58%) was documented in the resection specimens. The 1-, 2-, and 3-year overall survival rate was calculated as 84%. CONCLUSION:
|
Authors | A Eckardt, D Rades, V Rudat, C Hofele, R Dammer, B Dietl, I Wildfang, J H Karstens |
Journal | Mund-, Kiefer- und Gesichtschirurgie : MKG
(Mund Kiefer Gesichtschir)
Vol. 6
Issue 2
Pg. 117-21
(Mar 2002)
ISSN: 1432-9417 [Print] Germany |
Vernacular Title | Prospektive Phase-II-Studie zur neoadjuvanten Radiochemotherapie fortgeschrittener, operabler Mundhöhlenkarzinome. 3-Jahres-Ergebnisse. |
PMID | 12017874
(Publication Type: Clinical Trial, Clinical Trial, Phase II, English Abstract, Journal Article)
|
Topics |
- Adult
- Aged
- Carcinoma, Squamous Cell
(mortality, pathology, therapy)
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Female
- Humans
- Male
- Middle Aged
- Mouth Neoplasms
(mortality, pathology, therapy)
- Neoadjuvant Therapy
- Neoplasm Staging
- Oropharyngeal Neoplasms
(mortality, pathology, therapy)
- Radiotherapy, Adjuvant
- Survival Rate
|